Trials / Unknown
UnknownNCT03864705
Compliance of Diabetic Patients Treated With Metformin
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 400 (estimated)
- Sponsor
- Institute for Clinical and Experimental Medicine · Other Government
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Metformin is the 1st line treatment in all subjects with type 2 diabetes without a contraindication to its use. The compliance with the use of metformin is not optimal mainly owing to relatively frequent gastrointestinal side effects. However, hard data about the real compliance are currently not available. In this trial we aim at assessing the compliance with metformin intake using a combination of serum metformin measurement and a specific questionnaire. We will further evaluate the impact of different pharmacological forms of metformin (standard vs. XR - extended release) on its compliance and try to identify common characteristics associated with reduced compliance.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Measurement of plasma metformin levels | Subjects on chronic metformin therapy will have their plasma metformin levels measured during a regular check-up with glycated hemoglobin assessment. |
Timeline
- Start date
- 2019-03-01
- Primary completion
- 2021-12-31
- Completion
- 2021-12-31
- First posted
- 2019-03-06
- Last updated
- 2020-09-11
Locations
1 site across 1 country: Czechia
Source: ClinicalTrials.gov record NCT03864705. Inclusion in this directory is not an endorsement.